目的 探讨早期使用沙库巴曲缬沙坦对急性前壁ST段抬高型心肌梗死患者预后的影响.方法 选取2022年3月—2023年6月茂名市人民医院收治的50例急性前壁ST段抬高型心肌梗死患者为研究对象,按照随机数表法分为观察组和对照组,每组25例,观察组给予沙库巴曲缬沙坦钠片,对照组给予缬沙坦片.比较两组患者心功能指标、心肌损伤标志物水平、不良心血管事件以及不良反应发生的情况.结果 治疗后,观察组心功能相关的指标中,左心室舒张末期内径以及左心室收缩末期内径较对照组低,射血分数较对照组高,差异有统计学意义(P<0.05);治疗后,观察组心肌损伤标志物水平超敏肌钙蛋白以及B型钠尿肽较对照组低,差异有统计学意义(P<0.05);观察组不良心血管事件总发生率为4.00%低于对照组,差异有统计学意义(χ2=5.357,P<0.05);观察组不良反应总发生率低于对照组,差异有统计学意义(P<0.05).结论 对于急性前壁ST段抬高型心肌梗死患者使用沙库巴曲缬沙坦来进行治疗,能够显著的改善患者的心功能指标,促进患者心肌损伤的修复,降低患者不良心血管事件的发生,以及减少不良反应发生的情况.
Objective To explore the prognostic effect of early use of sacubitril valsartan on patients with acute ante-rior wall ST-segment elevation myocardial infarction.Methods 50 patients with acute anterior ST-segment elevation myocardial infarction admitted to Maoming People's Hospital from March 2022 to June 2023 were selected as the study objects,and were divided into observation group and control group according to random number table method,with 25 cases in each group.The observation group was given sarkubaktril sodium tablets,and the control group was given valsartan tablets.Cardiac function indexes,myocardial injury markers,adverse cardiovascular events and ad-verse reactions were compared between the two groups.Results After treatment,left ventricular end-diastolic diam-eter and left ventricular end-systolic diameter in observation group were lower than those in control group,and ejec-tion fraction was higher,with statistical significance(P<0.05).After treatment,the levels of hypersensitive troponin and B-type natriuretic peptide in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse cardiovascular events in the observation group was 4.00%,which was significantly lower than that in the control group(χ2=5.357,P<0.05).The total incidence of ad-verse reactions in the observation group was lower than that in the control group,and the difference was statistically significant(P<0.05).Conclusion For acute anterior wall ST-segment elevation myocardial infarction patients using sa-cubitril valsartan to carry out treatment,can significantly improve the patient's cardiac function index,promote the re-pair of myocardial injury,reduce the occurrence of adverse cardiovascular events in patients,as well as to reduce the incidence of adverse reactions.